updated 1/14/2011 6:18:22 AM ET 2011-01-14T11:18:22

SUNRISE, Fla., Jan. 14, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT)  (http://www.bioheartinc.com) today announced it is one of the presenters at the upcoming Phacilitate 7th Annual Cell & Gene Therapy Forum in Washington D.C. from January 24th – 26th. The 3 day conference program will feature a hybrid of business, regulatory and scientific topics, with speakers drawn from pharmaceutical and biotech companies, the regulators and cell and gene therapy developers. 

Kristin Comella, Bioheart's Chief Scientific Officer, will be presenting Bioheart's products for treating heart failure including MyoCell SDF-1, Bioheart's combined cell and gene therapy product approved by the FDA for a phase I trial.  Developing a combined cell and gene therapy product for commercial use is a novel and complex process. This session will discuss the Bioheart experience in taking combined cell and gene therapy products to the clinic and the challenges to ensure patient safety in the path to the commercialization.  This includes the recent validation studies that were completed to extend the shelf life of the MyoCath Catheter delivery system and the decision to conduct the REGEN MyoCell SDF-1 trial in the U.S. vs. offshore. 

About Bioheart, Inc:  

Bioheart, Inc., founded in 1999, seeks to be the "go to technology partner for heart failure specialists and their patients".  The company's flagship product MyoCell is an adult muscle stem cell composition, also known as immature myoblasts, derived and processed from patient's own thigh muscle. These cells are delivered to a patient's heart via the MyoCath needle tipped catheter or a similar device which is inserted through the patient's groin and is directed to the inside of the heart where the injections are made. MyoCell has been in clinical trials for treating advanced heart failure patients since early 2001. A 2nd generation composition MyoCell SDF-1 received FDA approval for clinical trials. This composition is made up of genetically modified cells that over express the stromal derived factor 1 protein that has been shown to improve blood vessel formation and muscle development. Bioheart, Inc. has also initiated clinical evaluation of methods of treating heart ischemia, acute myocardial infarctions and lower limb ischemia utilizing adipose (fat) derived cells.  Bioheart is focused on heart failure and has a building pipeline of product developments to assist care providers in treating and caring for these patients.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2009, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010.

CONTACT: Bioheart, Inc.
         Catherine Sulawske Guck, Chief Operating Officer
         954 835 1500
         email csguck@bioheartinc.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com